{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:15:20Z","timestamp":1793222120542,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.metabol.2022.155243","type":"journal-article","created":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T17:21:07Z","timestamp":1655659267000},"page":"155243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study"],"prefix":"10.1016","volume":"137","author":[{"given":"Celestino","family":"Sardu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Massimo Massetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cappabianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando Carlo","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Volpicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Ducceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Paolisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Marfella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2022.155243_bb0005","first-page":"1","article-title":"2018 ESC guidelines for the diagnosis and management of syncope the task force for the diagnosis and management of syncope of the european Society of Cardiology (ESC) developed with the special contribution of the european heart rhythm association (EHRA)","volume":"00","author":"Brignole","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.metabol.2022.155243_bb0010","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jamda.2012.12.001","article-title":"Predictors of mortality, rehospitalization for syncope, and cardiac syncope in 352 consecutive elderly patients with syncope","volume":"14","author":"Khera","year":"2013","journal-title":"J Am Med Dir Assoc"},{"issue":"152\u2013162","key":"10.1016\/j.metabol.2022.155243_bb0015","article-title":"Cardiac syncope recurrence in type 2 diabetes mellitus patients vs. normoglycemic patients: the CARVAS study","volume":"151","author":"Sardu","year":"2019","journal-title":"Diabetes Res Clin Pract."},{"issue":"31","key":"10.1016\/j.metabol.2022.155243_bb0020","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011757","article-title":"ELectrophysiological mechanisms underlying the Inhibitory CArdiac syncope without asystolic significant pause: therapeutic and prognostic implications. The ELICA randomized trial","volume":"97","author":"Sardu","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.metabol.2022.155243_bb0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2337\/diacare.7.5.447","article-title":"Autonomic neural dysfunction in recently diagnosed diabetic subjects","volume":"7","author":"Pfeifer","year":"1984","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.metabol.2022.155243_bb0030","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.2337\/dc21-0433","article-title":"Impact of admission hyperglycemia on heart failure events and mortality in patients with takotsubo syndrome at long-term follow-up: data from HIGH-GLUCOTAKO investigators","volume":"44","author":"Paolisso","year":"2021","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.metabol.2022.155243_bb0035","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/europace\/eus063","article-title":"Cardiac autonomic disturbances in patients with vasovagal syndrome: comparison between iodine-123-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability","volume":"14","author":"Kochiadakis","year":"2012","journal-title":"Europace"},{"issue":"22","key":"10.1016\/j.metabol.2022.155243_bb0040","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.metabol.2022.155243_bb0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/biomedicines8030043","article-title":"Comparative study of the effects of GLP1 analog and SGLT2 inhibitor against diabetic cardiomyopathy in type 2 diabetic rats: possible underlying mechanisms","volume":"8","author":"Hussein","year":"2020","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.metabol.2022.155243_bb0050","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004417","article-title":"Mechanisms of vasovagal syncope in the young: reduced systemic vascular resistance versus reduced cardiac output","volume":"6","author":"Stewart","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2022.155243_bb0055","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155243_bb0065","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium-glucose cotransporter2","volume":"35","author":"Matthews","year":"2017","journal-title":"J Hypertens"},{"issue":"54","key":"10.1016\/j.metabol.2022.155243_bb0070","article-title":"Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment","volume":"7","author":"D'Onofrio","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2022.155243_bb0075","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.1016\/j.metop.2020.100039","article-title":"Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis","volume":"7","author":"Garg","year":"2020","journal-title":"Metabol Open"},{"key":"10.1016\/j.metabol.2022.155243_bb0080","unstructured":"W Shimizu Y Kubota Y Hoshika K Mozawa S Tara Y Tokita et al. EMBODY trial investigators. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial."},{"issue":"8","key":"10.1016\/j.metabol.2022.155243_bb0085","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3390\/biomedicines9080904","article-title":"Metformin therapy effects on the expression of sodium-glucose cotransporter 2, leptin, and SIRT6 levels in pericoronary fat excised from pre-diabetic patients with acute myocardial infarction","volume":"9","author":"Sardu","year":"2021","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.metabol.2022.155243_bb0090","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155243_bb0095","first-page":"1620","article-title":"Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function","volume":"28","author":"Sisson","year":"1987","journal-title":"J Nucl Med"},{"key":"10.1016\/j.metabol.2022.155243_bb0100","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0002-9149(9X)00084-9","article-title":"Neurohormonal response to head-up tilt and its role in vasovagal syncope","volume":"79","author":"Jardine","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2022.155243_bb0105","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.hrthm.2016.03.018","article-title":"Spontaneous vs nitroglycerin-induced vasovagal reflex on head-up tilt: are there neuroendocrine differences?","volume":"13","author":"Nilsson","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.metabol.2022.155243_bb0110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/joim.12043","article-title":"Novel cardiovascular biomarkers in unexplained syncopal attacks: the SYSTEMA cohort","volume":"273","author":"Fedorowski","year":"2013","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.metabol.2022.155243_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0877-2","article-title":"Canagliflozin for japanese patients with chronic heart failure and type II diabetes","volume":"18","author":"Sezai","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.metabol.2022.155243_bb0120","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155243_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3474-5","article-title":"Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)","volume":"20","author":"Jensen","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.metabol.2022.155243_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3474-5","article-title":"Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)","volume":"20","author":"Jensen","year":"2019","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.metabol.2022.155243_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01209-y","article-title":"Effect of sodium\u2013glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis","volume":"20","author":"Yu","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.metabol.2022.155243_bb0140","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.2337\/dc15-0642","article-title":"Sodium\u2013glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside","volume":"38","author":"Mudaliar","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.metabol.2022.155243_bb0145","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155243_bb0150","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/HJH.0000000000002800","article-title":"Low-blood pressure phenotype underpins the tendency to reflex syncope","volume":"39","author":"Brignole","year":"2021","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2022.155243_bb0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/hr.2016.2","article-title":"A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats","volume":"39","author":"Takeshige","year":"2016","journal-title":"Hypertens Res"},{"key":"10.1016\/j.metabol.2022.155243_bb0160","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/hr.2017.14","article-title":"Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats","volume":"40","author":"Yoshikawa","year":"2017","journal-title":"Hypertens Res"},{"key":"10.1016\/j.metabol.2022.155243_bb0165","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2022.155243_bb0170","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155243_bb0175","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.metabol.2022.155243_bb0180","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jash.2017.07.005","article-title":"The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus","volume":"11","author":"Jordan","year":"2017","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.metabol.2022.155243_bb0185","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/nep.12620","article-title":"Is it time to think about the sodium glucose co-transporter 2 sympathetically?","volume":"21","author":"Elliott","year":"2016","journal-title":"Nephrology"},{"key":"10.1016\/j.metabol.2022.155243_bb0190","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J Cardiol"},{"key":"10.1016\/j.metabol.2022.155243_bb0195","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2147\/DMSO.S258593","article-title":"Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice","volume":"13","author":"Nguyen","year":"2020","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"11","key":"10.1016\/j.metabol.2022.155243_bb0200","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2337\/diacare.18.11.1415","article-title":"Adverse events and their association with treatment regimens in the diabetes control and complications trial","volume":"18","year":"1995","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155243_bb0205","article-title":"Sodium\/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts","volume":"18","author":"Marfella","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155243_bb0210","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.3389\/fphar.2021.777083","article-title":"Effects of sodium-glucose transporter 2 inhibitors (SGLT2-I) in patients with ischemic heart disease (IHD) treated by coronary artery bypass grafting via MiECC: inflammatory burden, and clinical outcomes at 5 years of follow-up","volume":"12","author":"Sardu","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049522001214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049522001214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:32:54Z","timestamp":1758429174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049522001214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":41,"alternative-id":["S0026049522001214"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155243","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"155243"}}